RAS gene expression in the case–control cohort was unaltered in relation to gender, hypertensive status, or RAS medication history (Supplementary Figures 13–15) except for ACE2/RG gene expression, which was significantly elevated in AD donors prescribed RAS-targeting medication (Dunn’s, p = .0495; Supplementary Figure 15D). This evidence concerns the gene ACE2 and Alzheimer disease.